GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco, January 12-15, 2026.
During these premier investor forums, GeoVax leadership will highlight the Company’s 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026, including key clinical catalysts, regulatory milestones, and business development. The presentation, scheduled for January 13, 2026 at 2:30 pm PST at the Hilton Union Square, will be webcast live and may be accessed here or through the Events & Presentations section of the company’s website.
GeoVax’s pipeline includes CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials targeting high-risk and immunocompromised populations, such as hematologic cancer patients and those with chronic lymphocytic leukemia. The company will discuss clinical status, translational data, and regulatory pathways for these populations.
In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Translational and clinical data supporting development in head & neck cancer and other high-value solid tumor indications will be presented.
The company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. Based on recent EMA regulatory guidance, GeoVax anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. Regulatory progress, clinical strategy, and potential registration pathways supporting civilian and biodefense use will be reviewed.
Manufacturing platform advancements in continuous cell-line manufacturing enabling scalable, resilient, and domestic vaccine production will be highlighted, along with partnership and collaboration opportunities to support pipeline advancement and long-term value creation.
“We are pleased to share GeoVax’s 2025 achievements with the global investor and biotech community at Biotech Showcase and the J.P. Morgan Healthcare Conference,” said David Dodd, President and CEO of GeoVax Labs, Inc. “Our team has delivered meaningful clinical and operational progress, strengthened our strategic position, and advanced multiple programs toward key inflection points in 2026. We look forward to engaging with shareholders, partners, and prospective collaborators on our differentiated pipeline and long-term growth strategy.”
GeoVax holds worldwide rights for its technologies and product candidates, supported by a strong IP portfolio. For more information, visit the company’s website at www.geovax.com.
